Early-stage classical Hodgkin lymphoma (HL) patients are evaluated by an end-of-chemotherapy positron emission tomography-computed tomography (eoc-PET-CT) after doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) and before radiation therapy (RT). We determined freedom from progression (FFP) in patients treated with ABVD and RT according to the eoc-PET-CT 5-point score (5PS). Secondarily, we assessed whether patients with a positive eoc-PET-CT (5PS of 4-5) can be cured with RT alone. The cohort comprised 174 patients treated for stage I-II HL with ABVD and RT alone. ABVD was given with a median of four cycles and RT with a median dose of 30Á6 Gy. Five-year FFP was 97%. Five-year FFP was 100% (0 relapses/98 patients) for patients with a 5PS of 1-2, 97% (2/65) for a 5PS of 3, 83% (1/8) for a 5PS of 4, and 67% (1/3) for a 5PS of 5 (P < 0Á001). Patients with positive eoc-PET-CT scans who were selected for salvage RT alone had experienced a very good partial response to ABVD. Risk factors for recurrence in this subgroup included a small reduction in tumour size and a 'bounce' in ≥1 PET-CT parameter (reduction then rise from interim to final scan). Thus, a positive eoc-PET-CT is associated with inferior FFP; however, appropriately selected patients can be cured with RT alone.
A common treatment strategy for early-stage classical Hodgkin lymphoma (HL) is combined modality therapy (CMT) with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) followed by consolidative radiation therapy (RT), as established by the seminal German Hodgkin Study Group (GHSG) trials Engert et al, 2010) . This approach results in long-term cure in the majority of patients, in whom minimizing therapy is appropriate to reduce the risk of late treatment-related toxicity. However, a small fraction of patients develops relapsed or refractory disease, which may be fatal. In this subgroup, intensified therapy is recommended to improve disease control. Thus, tools that enable responseadapted individualization of management are highly desirable to avoid over-or under-treatment.
Functional imaging with 18 F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) scans has become a standard tool for response assessment in HL. Multiple groups have shown that early resolution of FDG-avidity is associated with a decreased risk of disease relapse (Zinzani et al, 2006; Furth et al, 2009; Gallamini et al, 2014; Hutchings et al, 2014; Oki et al, 2014; Simontacchi et al, 2015) . Conversely, residual FDG-avidity at the completion of chemotherapy is associated with an increased risk of progression (Advani et al, 2007; Furth et al, 2009; Barnes et al, 2011) . In early-stage HL patients treated with CMT, an end-ofchemotherapy PET-CT (eoc-PET-CT) scan is performed routinely after the completion of ABVD and prior to RT. The Deauville 5-point score (5PS) is used to report disease response to chemotherapy. This score is based upon the FDG uptake of the tumour relative to two reference points within the individual patient: the mediastinal blood pool and the liver Cheson et al, 2014) . Typically, a 5PS of 1-3 is interpreted as a complete metabolic response, while a score of 4-5 is thought to represent residual active disease . While patients with a 5PS of 1-3 continue on to receive the planned consolidative RT, those with a 5PS of 4-5 are managed typically with salvage chemotherapy and autologous stem cell transplantation (ASCT). However, a 5PS of 4-5 represents a spectrum of disease response ranging from partial resolution to progression . Therefore, a more nuanced approach toward patients with a positive eoc-PET-CT may be needed.
Previous work has suggested that selected patients with residual FDG-avid disease after completion of chemotherapy may be salvaged with RT alone and spared intensive chemotherapy and ASCT. However, this work was completed primarily in the era preceding use of the 5PS (Sher et al, 2009; Engert et al, 2012) . A more recent publication using the 5PS showed that 5-year progression-free survival (PFS) was 97% vs. 78% for early-stage HL patients with a negative versus positive eoc-PET-CT, respectively (P < 0Á0001) (Ciammella et al, 2016) . Although the majority of these patients were treated with ABVD and RT, the cohort did include individuals treated with intensified chemotherapy and/or ASCT. The systemic therapy regimen administered influences the predictive accuracy of the eoc-PET-CT; therefore, this study did not provide the outcomes of a cohort treated with ABVD and RT alone.
The current study aimed to assess freedom from progression (FFP) in early-stage HL patients treated with ABVD and RT only, according to the 5PS of the eoc-PET-CT. Secondarily, it aimed to determine whether selected patients with residual PET-positive disease after ABVD (5PS of 4-5) could be cured with RT alone and spared intensive salvage chemotherapy and ASCT. Lastly, it characterized the patients with a positive eoc-PET-CT who were selected for treatment with RT alone and explored innovative factors predictive of successful salvage with RT in this subgroup.
Methods

Patients
After Institutional Review Board approval was obtained, all patients seen at our institution for Ann Arbor stage I-II HL from 1 January 2003 to 31 December 2014 were identified retrospectively. Eligibility criteria for this study included: age ≥18 years, treatment with upfront ABVD or ABVD-like chemotherapy and RT, and availability of an analysable FDG-PET-CT scan performed after chemotherapy and before RT (eoc-PET-CT). RT was given according to the involved site technique . Clinical information was retrieved from electronic medical records.
Definitions
Bulky disease was defined as a tumour diameter of >10 cm in any dimension. FFP was defined as the time from initial diagnosis to diagnosis with relapsed/refractory disease. The eoc-PET-CT was performed after the completion of all cycles of ABVD, and PET-positivity was defined as a 5PS of 4 or 5.
PET-CT acquisition
Patients fasted for at least 6 h and were confirmed to have a blood glucose level of <8Á325 mmol/l prior to the FDG injection. For the FDG-PET-CT scan, patients were positioned supine. The FDG dose was 555-629 MBq for 2D imaging and 333-407 MBq for 3D imaging. Emission scans were acquired between 60 and 90 min after the FDG injection. Standard, vendor-provided reconstruction algorithms were used for PET images. CT images were acquired in helical mode during suspended mid-expiration. All PET-CT scanners underwent routine quality assurance.
PET-CT analysis
All PET-CT scans were interpreted by trained Nuclear Medicine Radiologists. A 5PS was assigned as reported previously Cheson et al, 2014) . Two investigators performed exploratory PET-CT analyses using MIM software version 6.4.9 (MIM Software Inc, Cleveland, OH). The maximum body weight standardized uptake value (SUV) of the disease was recorded. The metabolic tumour volume (MTV), defined as all disease with an SUV ≥ 2Á5 (Freudenberg et al, 2004) , was automatically contoured using a threshold segmentation method. The total lesion glycolysis (TLG) was defined as MTV 9 mean SUV of the MTV. The soft tissue volume (STV), defined as all abnormal tissue noted on the CT scan, was contoured manually. The reduction in each parameter was defined as 1 À (value from final PET-CT/corresponding value from initial PET-CT).
Statistical methods
The primary outcome was FFP, defined as the time from initial diagnosis to diagnosis with relapsed/refractory disease. If no event occurred, patients were censored at the time of last follow-up. Survival analyses were performed using Kaplan- Meier methods and compared using the log-rank test. Univariate Cox proportional hazard models were used to determine the effect of covariates on FFP. Categorical and continuous variables were compared using Fisher's exact test and the two-tailed t-test, respectively. Analyses were conducted using SPSS software (Version 22.0; IBM Corporation, Armonk, NY).
Results
Patient, disease, and treatment information
During the study period, 396 patients aged at least 18 years were seen at our institution for a diagnosis of early-stage HL. Of these, 174 patients were treated with ABVD and RT and had an available, analysable eoc-PET-CT scan. These patients comprised the study cohort.
The characteristics of the cohort are summarized in Table I . The median age at diagnosis was 31 years (range: 18-83). Disease was stage II in 142 (82%). B symptoms were present in 53 patients (31%) and bulk in 52 (30%). Patients received a median of four cycles of ABVD (range: 2-6), and RT was to a median dose of 30Á6 Gy (range: 20-42Á2 Gy). The post-chemotherapy 5PS was 1-2 in 98 patients (56%), 3 in 65 (37%), 4 in 8 (5%), and 5 in 3 (2%). Patients with a positive eoc-PET-CT who were treated with salvage chemotherapy/ASCT did not meet the inclusion criteria for this study and, therefore, are not represented in this group. This separate cohort is described below.
Patient outcomes
At a median follow-up of 53 months (range: 7-146), four events were observed. Two disease relapses were local (i.e. within the RT field), one was distant, and one was both local and distant. The 5-year actuarial FFP was 97% (95% confidence interval: 94-100%). As shown in Table II and Fig 1, the post-chemotherapy 5PS was significantly associated with FFP (P < 0Á001). The 5-year FFP was 100% for patients with a 5PS of 1-2, 97% for a 5PS of 3, 83% for a 5PS of 4 and 67% for a 5PS of 5.
eoc-PET-positive subgroup
Patients with a positive eoc-PET-CT after the completion of ABVD are typically considered for salvage chemotherapy and ASCT. We aimed to characterize the patients with residual PET-positive disease who were selected for treatment with RT alone and, therefore, were included in this cohort. Thus, we identified a comparison group comprising the patients who were managed during the same time period, had a positive eoc-PET-CT, and were treated with salvage chemotherapy/ASCT. A total of 15 patients met these criteria. It must be noted that these 15 patients who received salvage chemotherapy and underwent ASCT for primary refractory HL were not included in the survival analyses reported above.
The characteristics of patients with a positive eoc-PET-CT who were managed with these two approaches are compared in Table III . Patients treated with salvage chemotherapy/ ASCT were significantly more likely to have undergone a biopsy after completion of ABVD and to have pathologically confirmed refractory HL. Those selected for RT alone had a lower burden of persistent disease on the eoc-PET-CT. For example, the median final MTV was 2Á2 ml vs. 14 ml and median final STV was 21 ml vs. 50 ml in patients treated with RT alone versus salvage chemotherapy/ASCT. Every patient selected for RT alone had experienced a very good partial response to ABVD. Comparing the eoc-to the prechemotherapy PET-CT, the median reduction in MTV was 99% and in STV was 85%. In one patient treated with RT, there was an increase in SUV max from the pre-chemotherapy to eoc-PET-CT; however, the area of increased FDG-avidity was of small volume, reflected by the significant reduction in MTV. All patients with stable or progressive disease were treated with salvage chemotherapy/ASCT. These patients had higher risk disease, confirmed by their inferior outcomes, despite receipt of more intensive therapy. In the ASCT group, six patients (40%) experienced disease relapse after ASCT and 3 (20%) died of HL; in the RT group, 2 patients (18%) experienced disease relapse after RT and 1 (9%) died of HL.
The remainder of the analysis focused on the 11 patients with a positive eoc-PET-CT who were treated with RT only, without salvage chemotherapy or ASCT. All patients presented with stage II HL and 4 (36%) had bulky disease. These patients received a median of six cycles of ABVD (range: 4-6), and RT was to a median dose of 37Á8 Gy (range: 30Á6-42Á2 Gy). A biopsy was performed prior to RT for three patients (27%) and was positive for persistent HL in one case (9% of subgroup, 33% of biopsies).
After the completion of RT, 2 of 11 patients (18%) in this subset experienced disease progression. Of these, one relapse was local (i.e. within the RT field) and the second was both local and distant. Univariate analyses were performed to compare the two patients whose disease relapsed with the remaining nine patients who were salvaged successfully with RT. As shown in Table IV , the only factor that was significantly associated with FFP was change in STV. Specifically, patients whose disease progressed experienced a smaller reduction in tumour size during chemotherapy. The STV reduction ranged from 59 to 61% in patients whose disease relapsed, compared to 78-95% in patients whose disease did not relapse (P < 0Á001). ABVD, doxorubicin, bleomycin, vinblastine and dacarbazine; RT, radiation therapy; FFP, freedom from progression; 95% CI, 95% confidence interval.
Fig 1.
Freedom from progression as a function of the end-of-chemotherapy positron emission tomography-computed tomography Deauville 5-point score for patients selected for treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and radiation therapy (n = 174). Log-rank P < 0Á001. Table III . Characteristics of patients with positive eoc-PET/CT scans after ABVD who were selected for treatment with RT alone (n = 11; included in the current study cohort) versus salvage chemotherapy with ASCT (n = 15; not included in the current study cohort).
Characteristic RT alone (n = 11) Salvage chemotherapy/ASCT (n = 15) P Lastly, we evaluated the change in PET-CT parameters over the course of chemotherapy in patients who had a prechemotherapy, interim and eoc-PET-CT scan. Of the patients with a positive eoc-PET-CT who were treated with RT alone, nine had scans performed at these three time points, including the two patients who experienced a disease relapse after RT. With the caveat of small numbers, we observed that both patients whose disease relapsed experienced a 'bounce' in at least one PET or CT parameter, defined as a reduction in the value from the pre-chemotherapy to the interim scan followed by an increase in the value from the interim to the eoc-PET-CT scan (Fig 2) .
Discussion
In this cohort of early-stage classical HL patients treated with ABVD and RT, the post-chemotherapy 5PS was significantly associated with FFP. However, although patients with a positive eoc-PET-CT were at an increased risk of disease progression, the majority were salvaged with RT alone. The patients with residual PET-positivity who were selected for treatment with RT alone had experienced a very good partial response to ABVD and had only low volume residual FDG-avidity at the completion of chemotherapy. For this subgroup, the median reduction in STV was 85% and in MTV was 99%, reflecting a significant anatomic and metabolic response. Patients with highly refractory disease were not treated with this strategy and were not included in this cohort; instead, such patients were directed to salvage chemotherapy/ASCT. Thus, our data suggest that patients with an incomplete but good partial disease response to ABVD can be cured with RT alone, without the need for intensive chemotherapy or stem cell transplantation.
Previously published data support the conclusion that a significant proportion of HL patients with a positive eoc-PET-CT can be cured with RT. Sher et al (2009) reported on 73 patients with HL of any stage, who were treated with ABVD-based chemotherapy and RT. For the 13 patients with residual PET-positivity after ABVD, failure-free survival was 69% at 2 years after treatment with RT only. Similarly, in the GHSG HD15 trial, patients with advanced-stage HL were treated with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone (BEA-COPP). Subsequently, RT was given for patients with residual disease measuring ≥2Á5 cm that was PET-positive. For the 182 patients who met these criteria, PFS was 86Á2% at 2 years (Engert et al, 2012) . Thus, in both studies, RT effectively salvaged the majority of patients with persistent FDG-avid disease after chemotherapy. Of note, these studies pre-dated the routine use of the 5PS, so PET-positivity was defined as residual FDG uptake above the mediastinal blood pool for masses measuring >2 cm or above background for smaller masses (Juweid et al, 2007) .
The current study not only corroborates these previously published findings, but also provides valuable new information. Unlike these other studies, our work was conducted in the era of the Deauville 5PS. The 5PS allows accurate response assessment. Each patient acts as his or her own control, so inter-reader and inter-device inconsistencies are reduced (Barrington et al, 2010) . The 5PS has become the accepted standard for reporting disease response to therapy in HL. Therefore, our findings are applicable to early-stage HL patients treated with ABVD and RT in the current era.
Another study published in the era of the 5PS reported findings consistent with ours. Ciammella et al (2016) evaluated the prognostic role of the eoc-PET-CT in 165 early-stage HL patients treated with CMT. They found that 5-year PFS was 97% vs. 78% for patients with a 5PS of 1-3 vs. 4-5, respectively (P < 0Á0001). As in our study, the eoc-PET-CT 5PS was significantly associated with outcome; nonetheless,
Characteristic
No progression (n = 9) Progression (n = 2) P ABVD, doxorubicin, bleomycin, vinblastine and dacarbazine; MTV, metabolic tumour volume; RT, radiation therapy; STV, soft tissue volume; SUV max , maximum standardized uptake value; TLG, total lesion glycolysis. Table IV . Univariate analyses of factors associated with freedom from progression in the patients with residual PET-positive disease who were selected to receive salvage RT alone (n = 11).
the majority of patients with a positive eoc-PET-CT were salvaged successfully. In their study, most patients were treated with ABVD and RT; however, the cohort did include individuals treated with intensified chemotherapy (ex. BEA-COPP) and/or ASCT. Thus, our study is unique in that it provides the outcomes of a cohort treated uniformly with ABVD and RT alone. Furthermore, we analysed the subgroup of patients with a positive eoc-PET-CT who were treated with RT alone to identify factors that distinguished those who were salvaged effectively by RT from those who experienced a subsequent disease relapse. This assessment was limited by small patient numbers. Nonetheless, several features were notable. First, the only patient with biopsy-proven residual disease after chemotherapy experienced disease progression. Second, the two patients in this group whose disease relapsed after RT were those who had experienced the smallest reduction in STV over the course of ABVD. This finding supports previously published work showing that lack of reduction in tumour size is a risk factor for recurrence, independent of the Deauville 5PS (Kostakoglu et al, 2012; Milgrom et al, 2017) . Consistent with this result, in patients with a positive eoc-PET-CT who were treated with RT on the GHSG HD15 trial, a smaller reduction in size of the CT mass was associated with a higher risk of disease relapse (Kobe et al, 2014) . Our analysis was limited by the small number of patients; therefore, further study is needed to define quantitatively an adequate STV reduction in this setting. The final feature that distinguished the two individuals whose disease relapsed was that both experienced a 'bounce', defined as an increase in Fig 2. Relative change in positron emission tomography-computed tomography (PET-CT) parameters during the course of chemotherapy for the select group of end-of-chemotherapy-PET-positive patients who received salvage radiation therapy alone. The graphs demonstrate PET-CT measurements for patients with pre-chemotherapy (1), interim (2), and post-chemotherapy (3) scans (n = 9). The two patients with subsequent relapse (red and green) experienced a 'bounce' in ≥1 final PET or CT parameter, defined as a reduction in the value from the pre-chemotherapy to the interim scan followed by an increase in the value from the interim to the end-of-chemotherapy-PET-CT scan. one or more eoc-PET-CT parameters relative to interim scans. To the best of our knowledge, the prognostic implications of this 'bounce' phenomenon have not been reported previously.
We conclude that selected patients with a post-chemotherapy 5PS of 4-5, who have experienced a very good partial response to ABVD, can be salvaged with RT alone. Patients with biopsy-proven residual disease, poor tumour shrinkage, or a 'bounce' in any PET-CT parameter may not be optimal candidates for this approach. We hypothesize that (i) a positive biopsy after ABVD, (ii) a small reduction in tumour size, and/or (iii) an increase in SUV max , MTV, TLG or STV between the interim and final scan may signify that disease is truly refractory to chemotherapy. Conversely, in patients with a positive eoc-PET-CT who do not have these characteristics, persistent FDG-avidity may represent low-level, residual chemosensitive disease or post-treatment inflammation, so RT is more likely to be sufficient for cure.
In the present study, all patients were treated with ABVD and RT. This treatment approach is used routinely at our institution. For patients who achieve at least a good partial response to ABVD based on interim PET-CT scans, typically performed after two cycles, we continue treatment with the same chemotherapy. Then, based on the results of the eoc-PET-CT, the decision is made whether to proceed with the planned RT or with salvage systemic therapy in patients with persistent disease. However, recently published data support escalation of chemotherapy, prior to RT, as a part of frontline management in patients with a positive interim PET-CT. In the randomized European Organization for Research and Treatment of Cancer/Lymphoma Study Association/Fondazione Italiana Linfomi H10 trial, patients with a positive PET-CT after two cycles of ABVD received either continued ABVD followed by RT or intensification of chemotherapy with escalated BEACOPP followed by RT. In this interim PET-positive subgroup, patients treated with escalated BEA-COPP experienced significantly improved PFS (Andre et al, 2017) . Thus, it is possible that patients in our current study may have experienced superior outcomes with intensification of their systemic therapy. We have not adopted this approach as our standard practice, because we have observed excellent clinical outcomes with ABVD and RT, so we prefer to avoid the higher toxicity rates associated with BEACOPP. Nonetheless, escalation of chemotherapy may be appropriate, in some scenarios, to improve disease control after upfront therapy and reduce the need for salvage treatment.
The current work is not without limitations. First, the small number of events limited the statistical analyses. Second, the retrospective design predisposed to bias. For example, eoc-PET-CT data were not available for all patients treated with ABVD and RT during the study period, so it is possible that those patients with eoc-PET-CT scans did not accurately represent the complete population. For example, patients with equivocal interim PET-CT scans may have been more likely to be evaluated by an eoc-PET-CT and thus may have been over-represented in this study. Given these limitations, validation of our findings in larger patient populations and in prospective studies is encouraged.
Despite these limitations, our study has several strengths, including uniform therapy with ABVD or ABVD-like chemotherapy and RT and long patient follow-up. For the subgroup of patients with persistent PET-positive disease treated with RT alone, the minimum follow-up time was 30 months. Therefore, it is likely that all events were captured, since the majority of relapses occur within 2 years after treatment for early-stage HL .
Modern management of HL focuses on response-adapted individualization to minimize toxicity while maintaining high cure rates. Therapy may be de-escalated in the setting of chemosensitive disease, for example, by limiting the number of chemotherapy cycles or omitting RT. Conversely, therapy is intensified for refractory disease, typically with high-dose chemotherapy and autologous stem cell transplantation. Here, we have identified an intermediate group that has residual PET-positive disease after the completion of ABVD, but can be cured with RT alone. These patients can be spared the morbidity of high-dose chemotherapy and ASCT. Further work is needed to characterize this group, so they may avoid overly intensive therapy. 
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